医学
膀胱切除术
膀胱癌
阿替唑单抗
临床终点
内科学
安慰剂
肿瘤科
癌症
佐剂
顺铂
随机对照试验
外科
化疗
彭布罗利珠单抗
免疫疗法
病理
替代医学
作者
Francesca Jackson‐Spence,Charlotte Toms,Luke Furtado O’Mahony,Julia Choy,Lucy Flanders,Bernadett Szabados,Peter Schmid
出处
期刊:Future Oncology
[Future Medicine]
日期:2023-03-01
卷期号:19 (7): 509-515
被引量:9
标识
DOI:10.2217/fon-2022-0868
摘要
The standard-of-care for muscle-invasive bladder cancer is radical surgery with neoadjuvant cisplatin-based chemotherapy. Despite curative intent from these interventions, relapse rates post-surgery remain high, with approximately 50% of patients developing local or distant recurrence within 2 years of surgery and a 5-year survival of only 50–60%. Identifying patients who are high risk for relapse post-surgery is a priority. Monitoring patients for circulating tumor DNA (ctDNA) is a minimally invasive approach that appears attractive for selecting patients potentially suitable for adjuvant treatment with checkpoint inhibitors. IMvigor011 (NCT04660344) is a global, double-blind, randomized phase III study assessing the efficacy of atezolizumab (anti-PD-L1) versus placebo in patients with high-risk muscle-invasive bladder cancer who are ctDNA positive post-cystectomy. The primary end point is disease-free survival in participants who are ctDNA positive within 20 weeks of cystectomy.
科研通智能强力驱动
Strongly Powered by AbleSci AI